Provided by Tiger Trade Technology Pte. Ltd.

Alvotech

5.10
+0.08001.59%
Pre-market: 5.310.2100+4.12%07:19 EDT
Volume:3.87M
Turnover:20.65M
Market Cap:1.82B
PE:-8.39
High:5.53
Open:5.40
Low:5.10
Close:5.02
52wk High:9.25
52wk Low:2.94
Shares:357.00M
Float Shares:141.00M
Volume Ratio:6.31
T/O Rate:2.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6081
EPS(LYR):0.0964
ROE:--
ROA:2.19%
PB:-9.51
PE(LYR):52.93

Loading ...

Alvotech prices 22,666,667-share offering at $3.75 per share

Reuters
·
Jun 16

Alvotech - Prices Offering of 22.67 Mln Ordinary Shares at $3.75 per Share

THOMSON REUTERS
·
Jun 16

Alvotech TBA Spot Secondary; price range $3.75-$undefined

TIPRANKS
·
Jun 16

Alvotech Launches Public Offering, Private Placement of Ordinary Shares

MT Newswires Live
·
Jun 16

Alvotech Halts Use of ATM Prospectus Supplement While Keeping Jefferies Sales Agreement Intact

TIPRANKS
·
Jun 16

Alvotech launches USD 125 million public share offering, concurrent private placement

Reuters
·
Jun 16

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

THOMSON REUTERS
·
Jun 16

Alvotech Sa: to Use Net Proceeds From Offering & Concurrent Private Placement to Fund Continued Development of Its Biosimilar Assets

THOMSON REUTERS
·
Jun 16

Why Alvotech (ALVO) Is Up 17.8% After FDA Advances Its Entyvio Biosimilar AVT16 Application

Simply Wall St.
·
Jun 14

Alvotech Wins FDA Review for Entyvio Biosimilar AVT16 as Q1 2026 Results Filed

TIPRANKS
·
Jun 09

Alvotech Says FDA Agreed to Review Application for Biosimilar of Entyvio; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 08

Reg-Alvotech Announces FDA Acceptance of Biologics License Application for Avt16, a Proposed Interchangeable Biosimilar to Entyvio®

THOMSON REUTERS
·
Jun 08

Alvotech says FDA accepts AVT16 biosimilar application for review

Reuters
·
Jun 08

Alvotech Resubmits US Market Applications for Johnson & Johnson and Regeneron Biosimilars

Deep News
·
Jun 05

Nordic Stocks Gain; Alvotech Leads Increases

Dow Jones
·
Jun 05

Alvotech, Teva Resubmit 2 Proposed Biosimilar Applications to the FDA for Retinal Treatment

MT Newswires Live
·
Jun 04

Alvotech resubmits FDA biosimilar applications for Simponi, Eylea candidates

Reuters
·
Jun 04

Alvotech Announces Resubmission of U.S. Biologics License Applications for Avt05, a Proposed Biosimilar to Simponi® and Simponi Aria®, and Avt06, a Proposed Biosimilar to Eylea®

THOMSON REUTERS
·
Jun 04

Press Release: Main Results of 2026 Annual and Extraordinary General Meeting

Dow Jones
·
Jun 04

Alvotech (ALVO) Gets a Sell from Barclays

TIPRANKS
·
Jun 03